Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $99 | $55 | $259 | $331 |
| - Cash | $15 | $23 | $17 | $14 |
| + Debt | $30 | $36 | $11 | $12 |
| Enterprise Value | $114 | $67 | $252 | $329 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$72 | -$57 | -$64 | -$52 |
| % Margin | – | – | – | – |
| Net Income | -$75 | -$59 | -$66 | -$53 |
| % Margin | – | – | – | – |
| EPS Diluted | -4.06 | -4.72 | -6.23 | -6.96 |
| % Growth | 14% | 24.2% | 10.5% | – |
| Operating Cash Flow | -$69 | -$43 | -$57 | -$54 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$69 | -$43 | -$57 | -$54 |